Skip to main content

Depressive Disorder, Major

72
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
6
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
8
0
18
2
25
19
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 123 programs with unclassified modality

On Market (6)

Approved therapies currently available

Takeda
TRINTELLIXApproved
vortioxetine
Takeda
oral2013
390M Part D
Takeda
ACTOPLUS METApproved
pioglitazone and metformin hydrochloride
Takeda
oral2005
131K Part D
Eli Lilly and Company
CYMBALTAApproved
duloxetine hydrochloride
Eli Lilly and Company
oral2004
BUPROPION HYDROCHLORIDEApproved
bupropion
Unknown Company
oral2014
Takeda
VORTIOXETINE HYDROBROMIDEApproved
vortioxetine
Takeda
Takeda
VORTIOXETINEApproved
vortioxetine
Takeda
oral

Competitive Landscape

33 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
21 programs
2
9
5
2
Bupropion Hydrochloride Extended-releasePhase 4
Bupropion extended releasePhase 4
323U66 SR 150 mg tabletPhase 3
BupropionPhase 3
Paroxetine CRPhase 3
+16 more programs
Prevail Therapeutics
6
1
1
5
2
DuloxetinePhase 41 trial
sertralinePhase 41 trial
BrenipatidePhase 3Peptide1 trial
DuloxetinePhase 31 trial
Duloxetine HydrochloridePhase 31 trial
+10 more programs
Active Trials
NCT01389752Completed22Est. Sep 2011
NCT01389765Completed24Est. Aug 2011
NCT01460407Completed14Est. Dec 2011
+12 more trials
Pfizer
PfizerNEW YORK, NY
9 programs
3
1
4
Venlafaxine ERPhase 41 trial
Venlafaxine ERPhase 41 trial
sertralinePhase 4
sertralinePhase 41 trial
DVS SRPhase 35 trials
+4 more programs
Active Trials
NCT00406952Completed165Est. Aug 2007
NCT00163059Completed30Est. Dec 2005
NCT00275197Completed262Est. Jul 2007
+9 more trials
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
3 programs
2
EstrogenPhase 41 trial
sertralinePhase 4
Study of Genetic Differences in People With DepressionN/A1 trial
Active Trials
NCT00229463Completed200Est. Jan 2011
NCT00229450Completed17Est. Aug 2004
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
3 programs
1
LY2216684PHASE_1
LY2216684PHASE_1
duloxetinePHASE_3
Takeda
TakedaTOKYO, Japan
3 programs
1
ACTOPLUS MET(Pioglitazone)PHASE_25 trials
VortioxetinePHASE_2
VortioxetinePHASE_31 trial
Active Trials
NCT02098733Completed1,168Est. May 2014
NCT02098746Completed294Est. Jul 2014
NCT02024971Completed1,103Est. Nov 2013
+3 more trials
Alliance Pharmaceuticals
1 program
1
EstrogenPhase 4
Innovation Pharmaceuticals
1 program
1
GeneSight PsychotropicPhase 4
Genome & Company
Genome & CompanyKorea - Suwon
1 program
1
GeneSight PsychotropicPhase 41 trial
Active Trials
NCT02466477Completed542Est. Sep 2019
AbbVie
AbbVieNORTH CHICAGO, IL
12 programs
2
10
RapastinelPhase 31 trial
RapastinelPhase 31 trial
RapastinelPhase 31 trial
RapastinelPhase 31 trial
RapastinelPhase 31 trial
+7 more programs
Active Trials
NCT03352453Terminated138Est. Jun 2019
NCT02116361Completed258Est. Dec 2016
NCT02943564Completed658Est. Dec 2018
+9 more trials
Lundbeck
LundbeckDenmark - Copenhagen
7 programs
1
4
VortioxetinePhase 31 trial
VortioxetinePhase 31 trial
Vortioxetine 10 mg/dayPhase 31 trial
Vortioxetine 10 mg/dayPhase 31 trial
VortioxetinePhase 21 trial
+2 more programs
Active Trials
NCT02752178Completed393Est. Sep 2018
NCT02919501Completed55Est. Apr 2017
NCT03108625Completed94Est. Apr 2020
+3 more trials
Sunshine Biopharma
Sunshine BiopharmaQC - Varennes
1 program
1
Mitizodone Phosphate tabletsPhase 2/31 trial
Active Trials
NCT04984512Recruiting600Est. Nov 2027
Syndeio Biosciences
1
AGN-241751Phase 21 trial
Active Trials
NCT03586427Completed251Est. Aug 2019
Syneos Health
Syneos HealthNC - Morrisville
1 program
1
REL-1017Phase 21 trial
Active Trials
NCT03051256Completed62Est. Sep 2019
GSK
GSKLONDON, United Kingdom
15 programs
BupropionN/A1 trial
MAN/A
Ropinirole CRN/A1 trial
Bupropion HCl XL tablet 150mgPHASE_11 trial
GSK163090PHASE_11 trial
+10 more programs
Active Trials
NCT02039960Completed1Est. Jan 2014
NCT00285727Completed60Est. Oct 2007
NCT02698553Completed16Est. Jun 2016
+12 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
10 programs
BI 1358894PHASE_11 trial
BI 1569912PHASE_11 trial
BI 1358894PHASE_21 trial
BI 1358894PHASE_21 trial
BI 1569912PHASE_21 trial
+5 more programs
Active Trials
NCT03854578Completed73Est. Sep 2019
NCT04937829Completed59Est. Nov 2023
NCT04521478Completed389Est. Feb 2024
+5 more trials
Abbott
AbbottABBOTT PARK, IL
2 programs
Deep Brain StimulationN/A1 trial
Deep Brain Stimulation, Libra Deep Brain Stimulation SystemN/A1 trial
Active Trials
NCT01331330Completed9Est. Jan 2015
NCT00617162Terminated125Est. Jun 2015
Otsuka
OtsukaJapan - Tokushima
2 programs
Outcomes in MEasurement-Based TreatmentN/A1 trial
The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy UseN/A1 trial
Active Trials
NCT01141387Completed914Est. Aug 2010
NCT01141400Completed48,865Est. Oct 2010
Biogen
BiogenCAMBRIDGE, MA
2 programs
SAGE-217PHASE_31 trial
SAGE-217PHASE_31 trial
Active Trials
NCT04442490Completed543Est. Apr 2021
NCT04476030Completed440Est. Dec 2021
Electromedical Products International
Active Alpha-Stim CESN/A1 trial
Active Trials
NCT04963907Unknown230Est. Dec 2022
Neurotech Pharmaceuticals
1 program
Active Cervel Neurotech Multi-Coil Transcranial Magnetic StimulatorN/A1 trial
Active Trials
NCT01909232Completed92Est. Jul 2014
Q Therapeutics
Q TherapeuticsUT - Salt Lake City
1 program
L-dopa/CarbidopaN/A1 trial
Active Trials
NCT05909267RecruitingEst. Oct 2025
Biocorp
BiocorpFrance - Issoire
1 program
LF/Erinacine A-enriched Hericium/Plain chocolate + antidepressantN/A1 trial
Active Trials
NCT04179006Unknown120Est. Dec 2023
Magstim
MagstimUK - Carmarthenshire
1 program
Navigated Transcranial Magnetic StimulationN/A1 trial
Active Trials
NCT03795051Completed30Est. Sep 2019
NeuroQore
NeuroQoreCA - Mountain View
1 program
NeuroQore rTMS DeviceN/A1 trial
Active Trials
NCT02667041Completed20Est. Mar 2018
Verona Pharma
Verona PharmaUK - London
1 program
Psychoeducational Family InterventionN/A1 trial
Active Trials
NCT05988333Recruiting384Est. Sep 2026
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
RESPECT-DN/A1 trial
Active Trials
NCT01583400Completed131Est. Oct 2013
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
SSRIsN/A1 trial
Active Trials
NCT02023567Unknown2,400Est. Dec 2016
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
Treatment Package for First-Episode DepressionN/A1 trial
Active Trials
NCT05616559Recruiting800Est. Dec 2026
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Valence-Specific Ecological Momentary InterventionN/A1 trial
Active Trials
NCT06311136Recruiting200Est. Aug 2025

+3 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Genome & CompanyGeneSight Psychotropic
GSKBupropion extended release
PfizerDVS SR
PfizerDVS SR
TakedaPioglitazone
TakedaPioglitazone
Prevail TherapeuticsDuloxetine
TakedaPioglitazone
Boehringer IngelheimDuloxetine
PfizerVenlafaxine ER
TakedaPioglitazone
GSKBupropion Hydrochloride Extended-release
Prevail Therapeuticssertraline
TakedaPioglitazone
TakedaPioglitazone

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 20,243 patients across 50 trials

NCT02466477Genome & CompanyGeneSight Psychotropic

Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder

Start: Jun 2015Est. completion: Sep 2019542 patients
Phase 4Completed
NCT01477931GSKBupropion extended release

Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features

Start: Nov 2010Est. completion: Sep 201150 patients
Phase 4Completed

Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects

Start: Aug 2010Est. completion: Oct 201030 patients
Phase 4Completed

Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects

Start: Aug 2010Est. completion: Oct 201038 patients
Phase 4Completed
NCT00770835TakedaPioglitazone

Efficacy and Safety of Pioglitazone in Treating Subjects With Vascular Complications Associated With Type 2 Diabetes Mellitus.

Start: Mar 2009Est. completion: May 201139 patients
Phase 4Completed
NCT00835120TakedaPioglitazone

Pioglitazone for the Treatment of Bipolar Disorder and Comorbid Metabolic Syndrome or Insulin Resistance

Start: Mar 2009Est. completion: Apr 201334 patients
Phase 4Completed

Switching to Duloxetine in Patients With Depression

Start: Jun 2008Est. completion: Jul 2009242 patients
Phase 4Completed
NCT00770445TakedaPioglitazone

Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.

Start: May 2008Est. completion: Jul 2010121 patients
Phase 4Completed

Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression

Start: Feb 2007Est. completion: Aug 2008339 patients
Phase 4Completed
NCT00401726PfizerVenlafaxine ER

Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program

Start: Jun 2006Est. completion: Oct 2007537 patients
Phase 4Completed
NCT01588470TakedaPioglitazone

Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)

Start: Jun 2006Est. completion: Dec 2011130 patients
Phase 4Completed
NCT00316160GSKBupropion Hydrochloride Extended-release

Sexual Functioning Study With Antidepressants

Start: Sep 2004Est. completion: May 2005347 patients
Phase 4Completed

Study of Medication and Placebo Response in Major Depression

Start: Dec 200360 patients
Phase 4Completed
NCT00672919TakedaPioglitazone

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

Start: Nov 2003Est. completion: Aug 2004305 patients
Phase 4Completed
NCT00816218TakedaPioglitazone

Molecular Mechanisms of Type 2 Diabetes Mellitus

Start: Mar 2003Est. completion: Nov 200839 patients
Phase 4Completed

A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression

Start: Oct 2002Est. completion: Sep 2003163 patients
Phase 4Completed

Estrogen and Perimenopausal Depression

Start: Apr 2002Est. completion: Aug 200417 patients
Phase 4Completed
NCT00494312TakedaPioglitazone

Safety Study of Pioglitazone Compared To Glyburide on Liver Function

Start: Oct 2000Est. completion: Jun 20052,120 patients
Phase 4Completed
NCT00046020PfizerVenlafaxine ER

Study Evaluating Venlafaxine ER in Recurrent Depression

Start: Aug 2000Est. completion: Oct 20051,096 patients
Phase 4Completed

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

Start: Feb 2026Est. completion: Feb 20281,000 patients
Phase 3Recruiting

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

Start: Nov 2020Est. completion: Dec 2021440 patients
Phase 3Completed

A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)

Start: May 2020Est. completion: Apr 2021543 patients
Phase 3Completed

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

Start: Jul 2019Est. completion: Dec 20200
Phase 3Withdrawn

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Start: Oct 2018Est. completion: Jul 201950 patients
Phase 3Terminated

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Start: Aug 2018Est. completion: Jul 2019230 patients
Phase 3Terminated

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Start: Aug 2018Est. completion: Jul 2019363 patients
Phase 3Terminated

Study of Rapastinel as Monotherapy in Patients With MDD

Start: Jun 2018Est. completion: Jul 2019439 patients
Phase 3Terminated

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Start: Mar 2017Est. completion: Apr 202094 patients
Phase 3Completed

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Start: Feb 2017Est. completion: Dec 2018617 patients
Phase 3Completed

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

Start: Nov 2016Est. completion: Feb 20191,304 patients
Phase 3Completed

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

Start: Nov 2016Est. completion: Nov 2018429 patients
Phase 3Completed

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

Start: Nov 2016Est. completion: Dec 2018658 patients
Phase 3Completed

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

Start: Oct 2016Est. completion: Nov 2018465 patients
Phase 3Completed

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

Start: Aug 2016Est. completion: Apr 2022662 patients
Phase 3Terminated
NCT02709655LundbeckVortioxetine 10 mg/day

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD)

Start: May 2016Est. completion: Jan 2022683 patients
Phase 3Completed
NCT02709746LundbeckVortioxetine 10 mg/day

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Start: May 2016Est. completion: Jul 2019784 patients
Phase 3Completed

A Safety Study in Participants With Major Depressive Disorder

Start: Oct 2010Est. completion: Dec 2012608 patients
Phase 3Completed
NCT01153009TakedaVortioxetine

Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder

Start: Jun 2010Est. completion: Mar 2012614 patients
Phase 3Completed
NCT01156597TakedaPioglitazone

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

Start: Apr 2008Est. completion: Sep 201030 patients
Phase 3Completed

Paroxetine-referenced Study Evaluating Three Doses of DVS SR in Outpatients With MDD

Start: Jul 2007Est. completion: Feb 2009807 patients
Phase 3Completed
NCT00727857TakedaPioglitazone

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

Start: Jun 2007Est. completion: Aug 2008600 patients
Phase 3Completed
NCT00770653TakedaPioglitazone

Efficacy of Pioglitazone/Metformin Combination Therapy in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia.

Start: Apr 2007Est. completion: May 2009305 patients
Phase 3Completed
NCT00772174TakedaPioglitazone

Efficacy and Safety Study of Pioglitazone Combined With Metformin on Metabolic Syndrome in Subjects With Type 2 Diabetes

Start: Jan 2007Est. completion: Feb 2008418 patients
Phase 3Completed
NCT00770952TakedaPioglitazone

Efficacy of Pioglitazone and Glimepiride Combination Therapy in Treating Subjects With Type 2 Diabetes Mellitus.

Start: Dec 2006Est. completion: Dec 200891 patients
Phase 3Completed
NCT00368303GSKParoxetine CR

A Local Register Study For Major Depression Of Paroxetine Controlled Release

Start: Dec 2006362 patients
Phase 3Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Start: Dec 2006Est. completion: Oct 2008595 patients
Phase 3Completed

Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects

Start: Sep 2006Est. completion: Sep 200620 patients
Phase 3Completed

Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Start: Jul 2006Est. completion: Jan 2009237 patients
Phase 3Terminated

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

Start: Jun 2006Est. completion: Feb 2007450 patients
Phase 3Completed
NCT00376181TakedaPioglitazone

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

Start: Jun 2006Est. completion: May 200796 patients
Phase 3Terminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

25 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 20,243 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.